The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)

• Status: Enrolling by invitation
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression [1] measured by eGFR and albuminuria (A) [2].

The main current tasks include 1) estimation serum uric acid (SUA) level most potential preserving of kidney function 2) the new onset of gouts depending on SUA level, both in gouts' and CKD' objects 3) safety and side effects of target and ultralow SUA levels for evidence-based ULT optimal regime in CKD and non CKD with gout patients. 4) investigation of cardio vascular rick ratio depending on SUA level.

The tasks also include

1. to determine U-curve or directly proportional relationship between SUA and eGFR-EPI in CKD 1-4

2. to evaluate the new onset of goat which depends on SUA level and renal function In this study the optimal ULT for kidney function based on target SUA level in 30 months' treatment with either allopurinol or febuxostat will be determined.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Practice Prof D. Ivanov
• Collaborator: Dr. T. Bevzenko, Dr. O. Synyachenko, Dr. I. Golovach
• Treatments: Allopurinol; Febuxostat

Criteria

Inclusion Criteria:

• outpatient adults withgout and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)

• outpatient adults with CKD 1-4 stages and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)

Exclusion Criteria:

• CKD 5 stage

• heart failure III-IV NYHA

• stroke

• peripheral arterial disease

• obesity with BMI above 30 kg/m2

• hypertension 3 grade

• insulin-dependent DM

• any kind of cancer

• inpatient intensive unit patients.